Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itacitinib + gemcitabine + nab-paclitaxel
- Development stage
- Discontinued
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
itacitinib + gemcitabine + nab-paclitaxel is an investigational combination regimen consisting of itacitinib (INCB039110), a selective Janus kinase 1 (JAK1) inhibitor; gemcitabine, a nucleoside analog chemotherapy; and nab-paclitaxel, a nanoparticle albumin-bound formulation of paclitaxel. This combination is being studied primarily for the treatment of advanced solid tumors, including metastatic and locally advanced pancreatic cancer. Preclinical rationale centers on the role of cytokine-mediated JAK/STAT signaling in tumor growth and cachexia, which itacitinib targets, while gemcitabine and nab-paclitaxel act as cytotoxic agents. In phase Ib/II studies, this regimen showed an acceptable safety profile and clinical activity, with promising reductions in tumor size and disease control rates for pancreatic cancer patients[1][4][7].
- Other names
- itacitinib + gemcitabine + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyJAK1 (Janus kinase 1)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on itacitinib + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on itacitinib + gemcitabine + nab-paclitaxel.